Truist Securities Downgrades Aerie Pharmaceuticals to Hold
Truist Securities analyst Gregory Fraser downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Hold.
Related Posts
JP Morgan Upgrades Reinsurance Group to Overweight, Raises Price Target to $138
JP Morgan analyst Jimmy Bhullar upgrades Reinsurance Group (NYSE:RGA) from Neutral to Overweight and raises the price target from $137 to $138.
CORRECTION: Seanergy Maritime Hldgs Reported Q2 Adj. EPS $0.04, Inline
Seanergy Maritime Hldgs (NASDAQ:SHIP) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate. This is a 300 percent increase over earnings of $0.01 per share from the same period last
Roth Capital Maintains Buy on Translate Bio, Raises Price Target to $45
Roth Capital analyst Tony Butler maintains Translate Bio (NASDAQ:TBIO) with a Buy and raises the price target from $28 to $45.